ClinicalTrials.gg
Status unknownNCT05430386Updated Feb 14, 2023

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

A Phase 1 interventional study of HS-10241 in Non Small Cell Lung Cancer, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-14.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2022, registered Jun 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
174
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Carcinoma, Non-Small-Cell Lung by Hansoh Pharmaceutical Group Company Limited — 20 open to participants now, 22 under way, 8 of them phase 3. Carcinoma, Non-Small-Cell Lung · Hansoh Pharmaceutical Group Company Limited.

Planned enrollment
18th of 26
174 · median 272
Started
2022
with 1 other
Phase 1
11 of 26
10 open now
Registered
7th of 26
by date

Among the 26 studies in Carcinoma, Non-Small-Cell Lung by Hansoh Pharmaceutical Group Company Limited, this one is the 18th largest by planned enrollment, is one of 2 that started in 2022, is one of 11 in phase 1, and was the 7th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 26 studies in Carcinoma, Non-Small-Cell Lung by Hansoh Pharmaceutical Group Company Limited are open now, in 4 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Carcinoma, Non-Small-Cell Lung by Hansoh Pharmaceutical Group Company Limited, or all of them as a file.
02

Study summary

This study is conducted to determine the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-10241 when given together with Almonertinib in patients with EGFRm+ advanced NSCLC.

Read the detailed description

This is a phase Ⅰb, multicenter study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HS-10241 administered orally in combination with Almonertinib in patients with EGFRm+ locally advanced or metastatic NSCLC who have progressed following prior EGFR-TKI therapy.

The study consist of two parts: Part 1 is the dose escalation period to observe the safety, tolerance, PK characteristics and preliminary anti-tumor activity, and determine the maximum tolerated dose (MTD) or maximum applicable dose (MAD) of combined administration; Part 2 is the dose expansion period to select appropriate doses in different target populations and further evaluate the efficacy, safety, tolerance and PK characteristics of combined administration, and determine the phase II recommended dose (RP2D).

All patients will be carefully followed for adverse events during the study treatment and for 28 days after the last dose of study drug. Patients of this study will be permitted to continue therapy with assessments for progression once every 8 weeks, if the product is well tolerated and the subject has stable disease or better. Survival follow-up is recommended once every 12 weeks.

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • NSCLC, c-Met,
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women aged more than or equal to (≥) 18 years.
  2. Patients or cytologically confirmed with locally advanced or NSCLC.
  3. According to Recist1.1, at least 1 target lesion that should be without local treatment like irradiation or with definite progression after local treatment and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15mm)
  4. performance status of 0-1with no deterioration within 2 weeks before enrollment.
  5. Estimated ≥three months.
  6. Females of child bearing age should adapt adequate measures and should not be breastfeeding from the signing of to 6 months after the last treatment of the study. Male patients should be willing to use barrier contraception (i.e., condoms) from the signing of informed consent to 6 months after the last treatment of the study.
  7. Females must have a negative pregnancy test in 7 days prior to start of first dose if of or must have evidence of non-childbearing potential by fulfilling any one of the following criteria:

    1. defined as age more than 60 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.
    2. Women under 60 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more, following cessation of exogenous hormonal treatments, and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the postmenopausal range for the laboratory.
    3. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not by tubal ligation.
  8. Signed and dated Informed Consent Form. Specific inclusion criteria Part 1 Patients have previously received any EGFR TKI continuous treatment (such as Gefitinib, Erlotinib, Osimertinib or Almonertinib) and had disease progression by imaging recorded. Before the first dose, all patients must provide imaging evidence of disease progression during or after the last treatment period. Before the start of study treatment, patients need to provide all the following test results detected by tumor tissue or blood samples with disease progression during or after the last treatment: EGFR sensitive mutation (either exon 19 deletion or L858R mutation); T790M status (negative or positive). The above test results of local laboratories can be accepted without confirmation of the central laboratory. If there are no local laboratory test results, then tumor tissue or blood samples meeting the protocol requirements should be sent to the central laboratory for testing and the results should be obtained before the first dose of study drug.

Part2 Cohort 1 -Patients have previously received the 1st/2nd/3rd-generation EGFR TKI (only one kind of them) and had disease progression by imaging recorded with centrally confirmed EGFR mutation, T790M negative and MET-positive.

Cohort2- Patients have not received any systemic treatment of advanced NSCLC with centrally confirmed EGFR mutation and MET-positive.

Cohort3- Patients have previously received both 1st/2nd and 3rd-generation EGFR-TKI and had disease progression by imaging recorded with centrally confirmed EGFR mutation and MET-positive.

Cohort4-Patients have previously received the 1st/2nd-generation EGFR TKI continuous treatment (not received the 3rd-generation EGFR TKI treatment) and had disease progression by imaging recorded with centrally confirmed EGFR mutation, T790M positive and MET-positive.

*Definition of MET-positive (any one of the following): ① Fluorescence in situ hybridization (FISH): MET gene copy number ≥ 5 or MET/CEP7 ratio ≥ 2; ② Immunohistochemistry (IHC): ≥ 50% tumor cells MET 3+.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with any of the following:

    1. Previous or current treatment with drugs targeting the c-MET/HGF pathway.
    2. Any cytotoxic chemotherapy, agents, antitumor traditional Chinese Medicine and any other anticancer drugs for the treatment of advanced NSCLC within 14 days before the first dose of study drug; or requiring treatment with these drugs during the study.
    3. Any antitumor monoclonal antibody therapy within 28 days before the first dose of study drug.
    4. Local radiotherapy within 2 weeks of the first dose of study drug; receiving radiation to > 30% of the bone marrow or with a wide field of radiation within 4 weeks before the first dose of study drug.
    5. Pleural or peritoneal effusion requiring clinical intervention (except for effusion not requiring drainage or being stable after drainage for at least 14 days before the first dose of study drug). Pericardial effusion (except for effusion being stable after drainage for at least 14 days before the first dose of study drug).
    6. Major surgery within 4 weeks of the first dose of study drug.
    7. Spinal cord compression or (except for that being asymptomatic and stable for at least 4 weeks, not requiring for at least 2 weeks prior to start of study treatment and with no obvious edema around the tumor focus by imaging examination).
    8. Treatment with drugs that are predominantly strong inhibitors or inducers or sensitive substrates of CYP3A4 with a narrow therapeutic range within 7 days of the first dose of study drug; or requiring treatment with these drugs during the study.
    9. Currently receiving drugs known to prolong or may cause torsade de pointe; or requiring treatment with these drugs during the study.
    10. Currently receiving or requiring long-term treatment with warfarin (LMWH is allowed).
  2. Any unresolved toxicities from prior therapy greater than Grade 2 according to (CTCAE) 5.0 with the exception of alopecia or neurotoxicity.
  3. History of other primary , excluding:

    1. Malignancies that have been recovered and inactive for ≥5 years prior to inclusion with a very low risk of recurrence.
    2. Non-melanoma skin cancer or malignant freckle mole with adequate treatment and no evidence of disease recurrence.
    3. Carcinoma in situ with adequate treatment and no evidence of disease recurrence.
    4. Non prostate cancer with definite treatment.
  4. Inadequate bone marrow reserve or organ function, as demonstrated by any of the following laboratory values:

    1. (ANC) \<1.5×109 / L
    2. count \<90×109 / L
    3. \<90 g/L
    4. Total (TBL) > 1.5 × or > 3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases.
    5. One or both of (ALT) and Aspartate aminotransferase (AST) > 2.5 × upper limit of normal (ULN) or > 5 × ULN in the presence of liver metastases.
    6. Creatinine > 1.5 × ULN concurrent with \< 50 mL/min; confirmation of creatinine clearance is only required when creatinine is > 1.5 × ULN.
    7. (INR) > 1.5, and partially activated prothrombin time (APTT) > 1.5 × ULN.
    8. Serum albumin (ALB) \< 28 g/L
    9. Serum lipase or serum amylase > 1.5 × ULN.
  5. Any of the following cardiac criteria:

    1. Resting corrected QT interval (QTc) > 470 ms obtained from (ECG), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF). See Appendix G for fridericia formula.
    2. Any abnormalities in rhythm, conduction, or morphology of the resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval > 250 ms).
    3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, intractable hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval.
    4. (LVEF) ≤ 50%.
  6. Severe, uncontrolled or active cardiovascular diseases.
  7. Diabetes ketoacidosis or hyperglycemia hypertonic occurring within 6 months before the first dose of the study drug, or the glycosylated hemoglobin value ≥ 7.5% in the screening period.
  8. Severe or poorly controlled hypertension.
  9. Bleeding symptoms with apparent clinical significance or obvious bleeding tendency within 1 months prior to the first dose of study drug.
  10. Serious arteriovenous thrombosis events occurred within 3 months before the first dose.
  11. Severe infections occurred within 4 weeks before the first dose.
  12. Patients who have received continuous steroid treatment for more than 30 days within 30 days before the first dose, or need long-term (≥ 30 days) steroid treatment (except for asthma patients who need long-term inhaled glucocorticoids and patients with topical corticosteroids), or who have other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation
  13. Clinically severe gastrointestinal dysfunction that may affect drug intake, transport or absorption.
  14. The presence of active infectious diseases has been known before the first dose such as (the test result of virus surface antigen [HBsAg] in the screening stage is positive, and the test value of HBV-DNA is ≥ 2 × 103iu / ml; if the retested result after regular antiviral treatment has been reduced to 2 × 103 IU / ml or less, patients can be enrolled), , tuberculosis, syphilis, or HIV infection, etc.
  15. Hepatic encephalopathy, hepatorenal syndrome, or Grade B or more severe cirrhosis.
  16. Other moderate or severe lung diseases that may interfere with the detection or treatment of drug-related pulmonary toxicity or may seriously affect respiratory function.
  17. Previous history of serious neurological or mental disorders, including epilepsy, dementia or severe depression and any other status that may interfere in assessment.
  18. Women who are breastfeeding or pregnant or planned to be pregnant during the study period.
  19. History of to any active or inactive ingredient of HS-10241/Almonertinib or to drugs with a similar chemical structure or class to HS-10241/Almonertinib.
  20. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  21. Any disease or condition that, in the opinion of the investigator, would compromise the safety of the patient or interfere with study assessments.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
174 participants (estimated)

Study arms

  • Experimental
    Dose escalation and dose expansion

    HS-10241 in combination with Almonertinib

    Drug: HS-10241

Interventions

  • Dose escalation: HS-10241 and Almonertinib will be administered in combination. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression. Dose expansion: HS-10241 and Almonertinib will be administered in the dose identified in Part 1 to further investigate the safety, tolerability, pharmacokinetics, and efficacy of this combination therapy.

    Also known as: Almonertinib

06

What researchers measure

Primary outcomes

  1. Part1-To determine the maximum tolerated dose (MTD)

    MTD was defined as the previous dose level at which 2 out of 3 patients or 2 out of 6 patients experienced a DLT.

    Time frame: Up to day 28 from the first dose (4 weeks).

  2. Part2- Objective response rate (ORR )

    ORR was defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 4 weeks later, as assessed according to RECIST version 1.1.

    Time frame: From first dose until disease progression or withdrawal from study, assessed up to 24 months.

Secondary outcomes

  1. Incidence and severity of treatment-emergent adverse events

    Assessed by number and severity of adverse events as recorded on the case report form, vital signs, laboratory variables, physical examination, electrocardiogram, and NCI CTCAE v5.0.

    Time frame: From first dose until 28 days after the last dose

  2. Observed maximum plasma concentration (Cmax) after the first dose

    Cmax will be obtained following administration of the first dose of HS-10241 or Almonertinib on Cycle 1.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 first dose

  3. Observed maximum plasma concentration (C ss,max) after multiple dose

    C ss,max of HS-10241 or Almonertinib will be obtained on Day 1 of dosing in the second 28-Day cycle of therapy.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of dosing in the second 28-Day cycle of therapy

  4. Observed minimum plasma concentration (C ss,min) after multiple dose

    C ss,min of HS-10241 or Almonertinib will be obtained on Day 1 of dosing in the second 28-Day cycle of therapy.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of dosing in the second 28-Day cycle of therapy

  5. Time to reach maximum plasma concentration (Tmax) after the first dose

    Tmax of HS-10241 or Almonertinib will be obtained following administration of the first oral dose

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 first dose

  6. Time to reach maximum plasma concentration (T ss,max) after multiple dose

    T ss,max of HS-10241 or Almonertinib will be obtained on Day 1 of dosing in the second 28-Day cycle of therapy.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of dosing in the second 28-Day cycle of therapy

  7. Apparent terminal half-life (t1/2) after the first dose

    Apparent terminal half-life of HS-10241 or Almonertinib is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 first dose

  8. Area under plasma concentration versus time curve from zero to the 12 hour sampling time (AUC0-12) after single dose

    Area under the plasma concentration versus time curve from time zero to the 12 hour sampling time 12 at which the concentration of HS-10241 was at or above the lower limit of quantification (LLQ). AUC0-12 was to be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours post-dose on Day 1 first dose

  9. Area under plasma concentration versus time curve from zero to the 24 hour sampling time (AUC0-24) after single dose

    Area under the plasma concentration versus time curve from time zero to the 24 hour sampling time 24 at which the concentration of Almonertinib was at or above the lower limit of quantification (LLQ). AUC0-24 was to be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 single dose

  10. Objective response rate (ORR)- Part1

    ORR was defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 4 weeks later, as assessed according to RECIST version 1.1.

    Time frame: From first dose until disease progression or withdrawal from study, assessed up to 24 months.

  11. Disease control rate (DCR)

    Objective response was assessed by RECIST 1.1 thereby to evaluate disease control rate. Disease control was defined as the percentage of patients who have a best overall response (confirmed CR, PR, or stable disease for at least 5 weeks).

    Time frame: From first dose until disease progression or withdrawal from study, assessed up to 24 months.

  12. Duration of response (DoR)

    Duration of response assessed by RECIST 1.1. Duration of response was defined as the time from when the criteria for CR or PR were first met to the occurrence of an objective disease progression (PD) or death.

    Time frame: From first dose until disease progression or withdrawal from study, assessed up to 24 months.

  13. Progression-free survival (PFS)

    Progression of tumor was assessed by RECIST 1.1 thereby to evaluate progression free survival. Progression-free survival was defined as the time from date of first dose until the documentation of objective disease progression (PD) or death from any cause in the absence of progression (whichever occurred first), regardless of whether they subsequently received non-study anti-cancer therapy.

    Time frame: From first dose until disease progression or withdrawal from study, assessed up to 24 months.

  14. Overall survival (OS)-Part 2

    OS was defined as time from randomization until the date of death due to any cause.

    Time frame: From first dose until disease progression or withdrawal from study, assessed up to 24 months.

07

Study locations

1 of 1 sites recruiting
  • Shanghai Chest Hospital
    Shanghai, Shanghai 200032, China
    Recruiting
    • Zhonglin Chen, MD · Contactchestgcp@126.com · 021-22200000
    • Shun Lu, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Dec 2023, 23 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 23 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2022
First posted
Jun 24, 2022
StartActual
Jan 5, 2022
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2023
Last update
Feb 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05430386
Responsible party
Sponsor
First posted
Jun 24, 2022
Start date
Jan 5, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Feb 14, 2023

Study contacts

Shun Lu, MD
Contact
shun_lu@hotmail.com
86-21-22200000
Zhonglin Chen, MD
Contact
chestgcp@126.com
86-21-22200000 ext. 5455
Shun Lu, MD
principal investigator · Shanghai Chest Hospital
Jiahua Chen, MD
principal investigator · Hunan Cancer Hospital
Xiaorong Dong, MD
principal investigator · Wuhan Union Hospital, China
Ying Cheng, MD
principal investigator · Jilin Provincial Tumor Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: C-Met Inhibitor HS-10241

Start the discussion